Seeking Alpha

Matrixx Initiatives ups its buyout offer for ProPhase Labs (PRPH) by 14% to $1.60/share in cash...

Matrixx Initiatives ups its buyout offer for ProPhase Labs (PRPH) by 14% to $1.60/share in cash from its earlier offer of $1.40 that PRPH had rejected. Matrixx is a private firm that makes Zicam cold medicine, a competitor to PRPH's Cold-Eeze product line.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|